Session » (0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0735

A Real-World Study from the Greater Paris Clinical Data Warehouse

10:30AM-12:30PM: Abstract Number: 0744

Age and Sex Influence on Clinical Manifestations of Giant Cell Arteritis: Results from the ARTESER Registry

10:30AM-12:30PM: Abstract Number: 0758

Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0732

Blocking GM-CSF receptor alpha with mavrilimumab reduces production of growth factors involved in vascular remodeling in an ex-vivo model of temporal artery culture from patients with giant-cell arteritis (GCA)

10:30AM-12:30PM: Abstract Number: 0733

Cerebrovascular Accidents in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0741

Characteristics of African American vs. Non-African American Patients with Giant Cell Arteritis: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0752

Characterization of patients with polymyalgia rheumatica in the ARTESER giant cell arteritis cohort

10:30AM-12:30PM: Abstract Number: 0763

Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience

10:30AM-12:30PM: Abstract Number: 0759

Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study

10:30AM-12:30PM: Abstract Number: 0748

Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis?

10:30AM-12:30PM: Abstract Number: 0737

Effectiveness and Safety of Janus Kinase Inhibitors in Giant Cell Arteritis. Real-World Clinical Practice Study and Literature Review

10:30AM-12:30PM: Abstract Number: 0736

Effectiveness of Tocilizumab in strokes in patients with giant cell arteritis. Spanish multicenter study of clinical practice

10:30AM-12:30PM: Abstract Number: 0742

Exploring Racial Variation in the Clinical Manifestations of Giant Cell Arteritis: A Retrospective Single-Center Study

10:30AM-12:30PM: Abstract Number: 0761

Fast-Track Clinics Improve Visual Outcomes in Giant Cell Arteritis: A Meta-Analysis

10:30AM-12:30PM: Abstract Number: 0750

Fibrinogen as a biomarker in the diagnosis of giant cell arteritis and detection of flares

10:30AM-12:30PM: Abstract Number: 0764

Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery – Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-

10:30AM-12:30PM: Abstract Number: 0743

Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab

10:30AM-12:30PM: Abstract Number: 0734

Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study

10:30AM-12:30PM: Abstract Number: 0746

Impact of Frailty on Mortality in GCA and PMR: A Retrospective Cohort

10:30AM-12:30PM: Abstract Number: 0751

Impact of Treatment with Upadacitinib on Biomarkers Identified by Proteomics in Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0753

Incidence of Ischemic Vision Loss Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0740

Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients

10:30AM-12:30PM: Abstract Number: 0754

Is There a Seasonal Pattern in Giant Cell Arteritis? Revisiting the Evidence in a Large Monocentric Cohort of 1203 patients

10:30AM-12:30PM: Abstract Number: 0747

Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis

10:30AM-12:30PM: Abstract Number: 0749

Prevalence and characteristics of subclinical Polymyalgia Rheumatica in patients with Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0745

Prevalence and Clinical Significance of Low ESR and CRP in Giant Cell Arteritis: A Population Based Study

10:30AM-12:30PM: Abstract Number: 0738

Real World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0762

Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers

10:30AM-12:30PM: Abstract Number: 0755

Sex Differences in Subtypes of Vascular Involvement and Clinical Manifestations in Giant Cell Arteritis

10:30AM-12:30PM: Abstract Number: 0756

Stroke Characteristics in Giant Cell Arteritis and Takayasu Arteritis: A Multicenter Cohort Study of 108 Patients

10:30AM-12:30PM: Abstract Number: 0731

The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 0760

The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis

10:30AM-12:30PM: Abstract Number: 0757

The role of Methotrexate in the treatment of Giant Cell Arteritis: data from the ARTESER registry.

10:30AM-12:30PM: Abstract Number: 0739

Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations

« View all sessions from this meeting